Moleculin Biotech (NASDAQ:MBRX) has got investors on the edge of their seats. On Monday, April 22, the company said it made a “significant discovery” for lung cancer and will be discussing it on a conference call this Wednesday, April 24. On the news, MBRX stock shot up in premarket trade.
Now, at 2:38 PM, MBRX stock is up more than 150%.
MBRX Stock in the Clouds
Moleculin Biotech is a clinical stage pharmaceutical company based in Houston, Texas. MBRX has an extensive portfolio of oncology drug candidates, candidates primarily used for the treatment of tumors that are highly resistant.
Led by CEO Walter V. Klemp, Moleculin Biotech announced plans today to discuss its significant discovery for lung cancer on a 4:30 PM ET conference call on April 24. The company will also discuss recent corporate events and FDA Fast Track Designation, according to the press release.
Biotech investor or not, this is a huge announcement, and it is one many should tune in for on Wednesday. Judging by how much MBRX is flying, the market seems to realize just what a big deal this is.
According to Yahoo Finance, as of 2:44 PM, MBRX stock is trading at $2.80, which puts it up 152%. MBRX stock was up 8% in premarket trade on increased volume and was seen up as high as 158% at one point in the afternoon.
Ways to Listen to the News
There are ways for the general public to access the Moleculin Biotech conference call. According to the press release, individuals can listen through a live webcast—the link is available on the company’s website—or participants can dial the following numbers: (412) 858-4600 or (800) 860-2442.
Do you have any predictions for what Moleculin’s significant discovery for lung cancer is? Regardless of what it is, it will be interesting to see the direction MBRX stock takes after the conference call on Wednesday, April 24.
Will MBRX stock surge or plunge? Let us know what you think in the comments below!
Featured image: DepositPhotos © pressmaster